Improved survival with ipilimumab in patients with metastatic melanoma FS Hodi, SJ O'day, DF McDermott, RW Weber, JA Sosman, JB Haanen, ... New England Journal of Medicine 363 (8), 711-723, 2010 | 17053 | 2010 |
Improved survival with vemurafenib in melanoma with BRAF V600E mutation PB Chapman, A Hauschild, C Robert, JB Haanen, P Ascierto, J Larkin, ... New England Journal of Medicine 364 (26), 2507-2516, 2011 | 9065 | 2011 |
Nivolumab in Previously Untreated Melanoma without BRAF Mutation C Robert, GV Long, B Brady, C Dutriaux, M Maio, L Mortier, JC Hassel, ... New England journal of medicine 372 (4), 320-330, 2015 | 6024 | 2015 |
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma C Robert, L Thomas, I Bondarenko, S O'Day, J Weber, C Garbe, C Lebbe, ... New England Journal of Medicine 364 (26), 2517-2526, 2011 | 5409 | 2011 |
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria JD Wolchok, A Hoos, S O'Day, JS Weber, O Hamid, C Lebbé, M Maio, ... Clinical cancer research 15 (23), 7412-7420, 2009 | 3649 | 2009 |
Overall survival with combined nivolumab and ipilimumab in advanced melanoma JD Wolchok, V Chiarion-Sileni, R Gonzalez, P Rutkowski, JJ Grob, ... New England Journal of Medicine 377 (14), 1345-1356, 2017 | 3537 | 2017 |
Five-year survival with combined nivolumab and ipilimumab in advanced melanoma J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CD Lao, ... New England journal of medicine 381 (16), 1535-1546, 2019 | 3023 | 2019 |
Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma J Weber, M Mandala, M Del Vecchio, HJ Gogas, AM Arance, CL Cowey, ... New England Journal of Medicine 377 (19), 1824-1835, 2017 | 2193 | 2017 |
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F de Braud, J Larkin, ... New England Journal of Medicine 371 (20), 1877-1888, 2014 | 1977 | 2014 |
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F De Braud, J Larkin, ... The Lancet 386 (9992), 444-451, 2015 | 1537 | 2015 |
Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy AMM Eggermont, V Chiarion-Sileni, JJ Grob, R Dummer, JD Wolchok, ... New England Journal of Medicine 375 (19), 1845-1855, 2016 | 1424 | 2016 |
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study JD Wolchok, B Neyns, G Linette, S Negrier, J Lutzky, L Thomas, ... The lancet oncology 11 (2), 155-164, 2010 | 1412 | 2010 |
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial AMM Eggermont, V Chiarion-Sileni, JJ Grob, R Dummer, JD Wolchok, ... The lancet oncology 16 (5), 522-530, 2015 | 1339 | 2015 |
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial HL Kaufman, J Russell, O Hamid, S Bhatia, P Terheyden, SP D'Angelo, ... The lancet oncology 17 (10), 1374-1385, 2016 | 1284 | 2016 |
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study GA McArthur, PB Chapman, C Robert, J Larkin, JB Haanen, R Dummer, ... The lancet oncology 15 (3), 323-332, 2014 | 1197 | 2014 |
Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma C Robert, JJ Grob, D Stroyakovskiy, B Karaszewska, A Hauschild, ... New England Journal of Medicine 381 (7), 626-636, 2019 | 1153 | 2019 |
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study GV Long, KT Flaherty, D Stroyakovskiy, H Gogas, E Levchenko, ... Annals of Oncology 28 (7), 1631-1639, 2017 | 716 | 2017 |
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial MA Davies, P Saiag, C Robert, JJ Grob, KT Flaherty, A Arance, ... The Lancet Oncology 18 (7), 863-873, 2017 | 707 | 2017 |
Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma JD Wolchok, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, ... Journal of Clinical Oncology 40 (2), 127, 2022 | 612 | 2022 |
Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with … J Chesney, I Puzanov, F Collichio, P Singh, MM Milhem, J Glaspy, ... Journal of clinical oncology 36 (17), 1658, 2018 | 575 | 2018 |